Delivery Order SPE2DB22D1106-SPE2DB25FETD1

Award Date 6/12/25
Potential Completion Date 6/13/25
Potential Value $19K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $4,728.70 firm fixed-price contract is for the delivery of RUXIENCE 500 MG/50 ML VIAL 50ML, a specialty pharmaceutical product. The award has an ultimate completion date of November 1, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This is a Firm Fixed Price delivery order awarded to Amerisourcebergen Drug Corp by the Defense Logistics Agency (DLA), a defense agency, to provide RUXIENCE 500 MG/50 ML VIAL 50ML. The contract has a ceiling value of $8,895.73 and a period of performance through June 13, 2025. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that serves as a critical supplier of medical and pharmaceutical products to federal agencies. This delivery order is not associated with a set-aside...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Ruxience 500 mg/50 ml vials. The $5,674.50 firm-fixed-price delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that AmerisourceBergen holds with the DLA Troop Support Medical. This IDC serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide RUXIENCE 500 MG/50 ML VIAL 50ML. The contract has a firm fixed price of $3,913.76 and an ultimate completion date of June 5, 2025. The contract is not set aside for any small business designation. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,728.70 firm fixed price delivery order is for the supply of RUXIENCE 500 MG/50 ML VIAL 50ML, a pharmaceutical product. The contract has an ultimate completion date of December 28, 2023 and was awarded on December 27, 2023. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC)...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The contract is for the delivery of RUXIENCE 500 MG/50 ML VIAL 50ML, with a firm fixed price ceiling of $4,892.20 and a period of performance through June 11, 2025. This delivery order is not associated with a set-aside program. AmerisourceBergen Drug Corporation holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation. The $9,457.40 contract is for the delivery of RUXIENCE 500 MG/50 ML VIAL 50ML, a pharmaceutical product. AmerisourceBergen Drug Corp is the prime contractor and no set-aside designation was used. This delivery order falls under a larger indefinite delivery contract (IDC) valued up to $999,999,999.00 that was awarded solely to...
This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract is for the supply of Ruxience 500 mg/50 ml vials, a specialty pharmaceutical product, with a ceiling value of $1,418.64 and a period of performance through March 29, 2024. This delivery order is issued under a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of RUXIENCE 500 MG/50 ML VIAL 50ML. The $4,728.70 firm fixed-price delivery order was awarded on December 16, 2021 with an ultimate completion date of December 17, 2021. The contract does not have a set-aside designation. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant...
This federal contract award, with ID SPE2DB22D3501|SPE2DB25FTZ50, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,892.16 Firm Fixed Price delivery order is for the supply of RUXIENCE 500 MG/50 ML VIAL 50ML, a pharmaceutical product. The contract has an ultimate completion date of January 2, 2025. This award is associated with a larger Indefinite Delivery Contract (IDC) that...
  • SPE2DB22D1106
    Indefinite Delivery Contract
  • SPE2DB22D1106-SPE2DB25FETD1
    Delivery Order

This is a federal contract award issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $19,242.34 and is for the delivery of RUXIENCE 500 MG/50 ML VIAL 50ML. The contract is a Firm Fixed Price Delivery Order and is not set aside.

Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00. This prime contract, designated as SPE2DX, provides a comprehensive global pharmaceutical support vehicle with a performance period extending through December 2026. The IDC enables the company to supply a vast range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency and U.S. Coast Guard.

Generated 9/11/25, 11:06 AM